Here, our research aims to reveal therapeutic potential of CDK7 inhibition in CCA preclinical models and further elucidate the possibility of combining THZ1 with other inhibitors to enhance antitumor effect in CCA treatment. The gene discussed is CDK7; the disease is cholangiocarcinoma.